
Since Lundbeck went through a larger shift in its research and development division, the company has been busy scouting for assets that could fit in its new focus area, neuroinflammation or neuroimmunology.
This has resulted in the purchase of the phase I-ready antibody APB-A1 from the South Korean company Aprilbio, and Lundbeck's Head of Research and Development Johan Luthman is excited to finally have the first real candidate in the company's new area.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app